Lymphoproliferative Disorders, Myeloproliferative Disorders
Conditions
Keywords
Hematological malignancies, lymphoid, myeloid, multiple myeloma, anticancer drugs, sensitivity, new treatments
Brief summary
Hematological malignancies gather several various pathologies included myeloproliferative disorders (as acute myeloid leukemia (AML) or chronic myeloid leukemia (CML)) and lymphoproliferative disorders (as chronic lymphoid leukemia (CLL), non-Hodgkin lymphoma (NHL) and multiple myeloma (MM)) . Over the last decade, the treatments have evolved significantly but the overall survival remains limited, especially for the AML and MM patients. There's an ongoing imperative to continue in-vitro and in-vivo studies to better evaluate the anti-cancer drugs sensitivity and therefore improving the response to treatments and open new fields of application. The healthy control group will be contributing to produce some pertinent and significant data for the results of the index cases group. The investigators aim to analyze 10 differents drugs, common use in chemotherapy or immunotherapy and evaluate by 2 ways the sensitivity: first, Flow cytometry (cells apoptosis by Annexine V and propidium iodide) on fresh samples and in a second time, monitoring of the blasts in the mouse's blood after injection.
Interventions
BIOLOGICALBlood collection for the evaluation of the anti-drugs sensitivity
The M.D investigators and the medical team identify the patients ( index cases and healthy volunteers) in a medical appointment. They inform them, collect the non-opposition right and the blood samples: 5 mL heparin tube and 5 mL dry tube for each person , one time.
Sponsors
Hospices Civils de Lyon
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Index cases: patients with myeloproliferative or lymphoproliferative disorders. * Controls: patients without hematological disease, without chemotherapy ((≤ 5 years.) and without immunosuppressive treatment at the study time. * Age ≥ 18 y.o for all the patients
Exclusion criteria
* Age \< 18 y.o * Pregnant or breastfeeding woman * Patients deprived of their liberty by judicial or administrative decision.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evaluation of the sensitivity of 10 anti-cancer drugs | Through study completion, an average of 3 years | Sensitivity determined by in-vitro * Tumor cells mortality by Flow cytometry * Monitoring of the blasts in the mouse's blood after injection |
Countries
France
Contacts
Primary ContactCharles Pr DUMONTET, PhD, MD
Backup ContactMarc Pr BONNEFOY, MD
Outcome results
None listed